Contraceptive efficacy and safety of 52mg LNG-IUS for up to 8 years: findings from the Mirena Extension Trial
Source : https://www.ajog.org/article/S0002-9378(22)00729-3/fulltext
Availability of the data underlying this publication will be determined later according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, time point, and process of data access.
Conclusion: The 52-mg LNG-IUS, initially approved for 5 years, maintains high contraceptive efficacy, user satisfaction, and a favorable safety profile through 8 years of use.